Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 5,290

Document Document Title
WO/2012/005473A2
The present invention provides a method for preparing ε-caprolactam by using high-silica nano-plate zeolite. According to the present invention, the method prepares ε-caprolactam from cyclohexanone oxime by a gas-phase Beckmann rearran...  
WO/2011/138795A3
Processes for preparing (S)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxa mide and its intermediates are provided.  
WO/2012/000846A1
The present invention relates to the use of a composition comprising specific a-amino- ketones, H2O2, a H2O2 precursor or a peracid and optionally an activator as a bleaching mixture for textile materials or dishes either manually or in ...  
WO/2012/000608A2
The present invention relates to novel beta-aminoaldehyde derivatives of the formulae (I), (II) and (III), in which the substituents R1 to R5 and A have the meaning given in the description, to a novel process for their preparation, to i...  
WO/2011/161232A1
The present invention relates to an improved method for the preparation of 3-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)- amino]-ethoxy}- ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carbo xylic acid. The present ...  
WO/2011/159551A1
Processes for making hydrogenated products including caprolactame (CL) caprolactone (CLO) or 1,6-hexanediol (HDO) and derivative thereof from monoammonium adipate (MAA) and/or adipic acid (AA) obtained from a clarified diammonium adipate...  
WO/2011/159562A1
A process for making a hydrogenated product comprising caprolactone (CLO) and 1,6-hexanediol (HDO) and derivatives thereof from adipic acid (AA) obtained from fermentation broths containing diammonium adipate (DAA) or monoammonium adipat...  
WO/2011/159556A1
Processes for making caprolactam (CL) from monoammonium adipate (MAA) and/or adipic aicd (AA) obtained from a clarified diammonium adipate-containing (DAA- containing) fermentation broth or MAA-containing fermentation broth and convertin...  
WO/2011/091131A3
Processes for the preparation of eslicarbazepine acetate and intermediates thereof. Also provided are polymorphic forms of eslicarbazepine acetate and methods for their preparation.  
WO/2011/159555A1
Processes for producing caprolactam (CL) and derivatives thereof from adipic acid (AA) obtained from fermentation broths containing diammonium adipate (DAA) or monoammonium adipate (MAA).  
WO/2011/154696A1
Disclosed herein are methods of preventing or treating inflammatory diseases using 3 - aminolactam compounds, each with aromatic "tail groups". Compounds as defined by formulae (I) and (I'), and the medical uses of the compounds, are des...  
WO/2011/154695A1
Disclosed herein are methods of preventing or treating inflammatory diseases using sulfonamide analogs of 3-aminolactam compounds, each with aromatic "tail groups". Compounds as defined by formulae (I) and (Ι'), and the medical uses of ...  
WO/2011/151436A2
The present invention is directed to novel compounds of formula (I) Ar1__L1__R__Ar2__Ar3 and their use in treating and/or preventing inflammatory, gastrointestinal and/or metabolic disorders.  
WO/2011/153206A1
Processes and intermediates for preparing salts of the 5-HT2C-receptor agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, and pharmaceutically acceptable solvates and hydrates thereof, that are useful for, inter alia, wei...  
WO/2011/138795A2
The present invention relates to a process for the preparation of (S)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxa mide compound of formula (1).  
WO/2011/138625A1
Process for the synthesis of Ivabradine salts of formula (I) the chemical name of which is: 3-{3-[((S)-3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-triene- 7-ylmethyl)-methyl-amino]-propyl}-7,8-dimethoxy-1,3,4,5-tetr ahydro-2H-3-benzazepine-2-...  
WO/2011/104723A3
Provided are the novel acid addition salts of ivabradine of formula I including their hydrates, solvates, anhydrous form, and non-solvated form, all in amorphous or crystalline forms.  
WO/2011/137089A1
Disclosed are pyruvate kinase M2 activators which are compounds of Formula (I), including those of Formula (II), wherein A1, A2, L, R, R1 to R3, X1 to X3, k, n, and m are as defined herein, that are useful in treating a number of disease...  
WO/2011/136484A1
Provided are novel organic electroluminescent compounds and an organic electroluminescent device using the same. Since the organic electroluminescent compound exhibits high luminous efficiency in blue color and excellent life property, i...  
WO/2011/132171A1
The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups ...  
WO/2011/131315A1
The invention relates to a process for the asymmetric transfer hydrogenation of a ketone substrate to produce as chiral secondary alcohol with an ee of greater than 85% in which an enantio-enriched chiral catalyst containing ruthenium or...  
WO/2011/117885A1
The present invention provides a process for the preparation of eslicarbazepine and rlicarbazepine and their acetates by resolution of racemic licarbazepine using acetyl mandelic acid.  
WO/2011/115378A1
Disclosed are organic electroluminescent compounds and organic electroluminescent devices employing said compounds. The organic electroluminescent compounds of the invention are defined by chemical formula [1], Chemical Formula 1 The com...  
WO/2011/108251A1
An epsilon-caprolactam manufacturing method capable of manufacturing in good yield, high-quality epsilon-caprolactam containing less impurity has an epsilon-caprolactam purification step A of obtaining purified epsilon-caprolactam from r...  
WO/2011/104723A2
The present invention provides novel acid addition salts of ivabradine of formula (I), including their hydrates, solvates, anhydrous form, and non solvated form, both in amorphous and crystalline forms.  
WO/2011/105700A1
Provided are novel organic electroluminescent compounds, and organic electroluminescent devices comprising the same. Since the organic electroluminescent compounds exhibit high luminous efficiency in blue color, and excellent life proper...  
WO/2011/101558A1
The invention relates to a method for synthesizing ivabradine of formula (I) and the pharmaceutically acceptable acid addition salts thereof.  
WO/2011/099606A1
A photoelectric element includes a conductive layer, an organic photoelectric layer, a blocking layer and a transparent conductive layer, the organic photoelectric layer contains a p type organic photoelectric material having a glass tra...  
WO/2011/100232A1
Disclosed is an ionic liquid formula (I): wherein: n is 1 or 2; R1 is selected from H and (C1-C6)alkyl; R2 is selected from -(CH2)wO[(CH2)xO(CH2)y]m(CH2)zCH3 and wherein w is 1 to 6, x is 1 to 6, y is 0 to 6, z is 0 to 6, m is 0 to 3 and...  
WO/2011/098582A2
The present invention relates to novel crystalline forms of ivabradine hydrochloride and pharmaceutical compositions prepared therefrom.  
WO/2011/093603A1
Provided are a novel organic electroluminescent compound and an organic electroluminescent device using the same. Since the organic electroluminescent compound exhibits good luminous efficiency and excellent life property, it may be used...  
WO/2011/091131A2
Processes for the preparation of eslicarbazepine acetate and intermediates thereof. Also provided are polymorphic forms of eslicarbazepine acetate and methods for their preparation.  
WO/2011/083304A1
The present invention concerns prodrugs of opioid analgesics and pharmaceutical compositions containing such prodrugs. Methods for providing more consistent pain relief by increasing the bioavailability of the opioid analgesic with the a...  
WO/2011/078668A1
The invention relates to a method for preparing caprolactam comprising recovering a mixture containing 6-aminocaproic acid, from a culture medium comprising biomass, and thereafter cyclising the 6-aminocaproic acid in the presence of sup...  
WO/2011/022508A3
Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, inf...  
WO/2011/071136A1
A therapeutic agent for fibromyalgia, comprising a 5-HT2C receptor agonist as an active ingredient.  
WO/2011/069944A1
This invention relates to organic, analytical and pharmaceutical chemistry. In particular to crystalline (2R)-2-{[1-({[(3S)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydr o-1H-1-benzazepin-3-yl]-amino}carbonyl)cyclopentyl]methyl}-4 -(1-naphth...  
WO/2011/022509A3
Provided are compositions and methods useful for modulation of signaling through the Toll- like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, in...  
WO/2011/067219A1
Compounds of the Formula (I), wherein m, n, X1, X2, Y1, Y2, R1 and R2 are as defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.  
WO/2011/045648A3
Disclosed herein an enzymatic process for preparing (S)-(-)-10-acetoxy-10,11- dihydro-5H-dibenz[b,f]azepine-5-carboxamide (eslicarbazepine) and its esters thereof. Further, the invention provides novel intermediates of eslicarbazepine an...  
WO/2011/060113A1
The invention relates generally to optical agents for biomedical applications, including phototherapy. Provided are sulfenamide compounds having an acyclic S-N bond with at least one aromatic and/or heterocyclic aromatic group providing ...  
WO/2011/052519A1
Disclosed is a novel benzazepine compound or a salt thereof, which has excellent vasopressin antagonist activity. Specifically disclosed is a benzazepine compound or a salt thereof, which is represented by general formula (1). (In genera...  
WO/2011/045648A2
Disclosed herein an enzymatic process for preparing (S)-(-)-10-acetoxy-10,11- dihydro-5H-dibenz[b,f]azepine-5-carboxamide (eslicarbazepine) and its esters thereof. Further, the invention provides novel intermediates of eslicarbazepine an...  
WO/2011/035355A1
The present invention relates to novel 3-azabicyclo[3.2.2]nonane derivatives of the general formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the specification....  
WO/2010/144862A3
The present invention generally relates to processes for the chemocatalytic conversion of a glucose source to an adipic acid product. The present invention includes processes for the conversion of glucose to an adipic acid product via gl...  
WO/2011/033194A1
The invention relates to a method for synthesizing ivabradine of formula (I) and to the addition salts thereof with a pharmaceutically acceptable acid.  
WO/2011/034078A1
Disclosed is a compound which is useful as the active ingredient of a medicinal composition, in particular, a medicinal composition for preventing and/or treating a VAP-1 associated disease. As the results of intensive studies on compoun...  
WO/2010/129057A8
The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical compositi...  
WO/2011/022509A2
Provided are compositions and methods useful for modulation of signaling through the Toll- like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, in...  
WO/2011/022508A2
Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, inf...  

Matches 301 - 350 out of 5,290